Member Info for BuenaVista

Sorry to hear about your husband Bella. Sending best wishes to him, and you.

Is he on a trial or is that normal for the treatment he's getting? I guess any targetted chemo treatment may need to be started cautiously in case the cyctotoxin goes off target for a particular patient. I wonder if this is a concern for Avacta and the clinicians - that rogue physiology which will metabolise the drug differently or 'hidden' stores of FAP-rich tissues located elsewhere in the body. Maybe AVA6000 will, in practice, also be started cautiously until it's seen how each individual patient's body reacts. Not really a problem as the course of treatment could be very long.

Astute chap this JAdams. What's your target price for buying back in at mate?

I don't come to this lice- infested place too often. What's happened to Haggis's inheritance that he invested in AFC?

Ade, Daz, and Garonne, a curious affair, - In a tangled web of secrecy, they dare to share. - A menagerie a trois, they claim not to know, - Yet, in their enigma, which two in truth do show?

Is it Ade and Daz, their passions intertwined, - With Garonne as the phantom, a sphincter behind? - Their love a hidden fire, burning fierce and bright, - A secret rendezvous, concealed from the light.

Or maybe it's Daz and Garonne, hand in hand, - With Ade as the illusion, the castles in the sand. - Their bond a whispered secret, a love unspoken, - In the shadows of the night, their hearts are awoken.

And what if it's Ade and Garonne, their love discreet, - With Daz as the illusion, their charade complete? - Their hearts entwined in a dance of sweet desire, - In the depths of their connection, they conspire.

In this tangled trio, where all roles are played, - The truth remains elusive, like a masquerade. - Ade, Daz, and Garonne, their secrets they keep, - In the mystery of their love, their secrets run deep.

So, which two among them share a lover's embrace? - In this complex tale of passion, we can't erase, - The many possibilities, the intrigue they decree, - A menagerie a trois, a bunch of vermin all three.

What an odd person.🫤

Yeah, Twitter best avoided or mocked. Not serious investment advice.

SNewby, yes, it is impossible, despite the use of magic calculators on Twitter. Best to just wait and see what the share price does, what licence deals are struck (if Alan's inkwell hasn't completely dried up by now) and what but out offers come in.

Yes Ice, but SNewby is making the case for 38 years' time, not today or next week or even next year.

SNewby, are you factoring in Pfizer dividends, currently at 5%, over those 38 years? Also, are you factoring in holding Avacta until 2061 or just until next week? 😂😂😂

TW really does need to vet these 🤡s for intelligence before sending them into the lions' den. 😂

Did TW send you?

Hmm... Don't think I'm going to learn anything useful from this joker. Congratulations LifeOfPI on qualifying for the green bin .

Congratulations LifeOfPI on being spiked. You know this is heading back down to 90p? Terry said so.

Noticeable who else isn't celebrating the definite move in the share price.

No doubt they will turn up again if the share price slips back.

It looks like we share roughly the same starting dose opinion JT but by different routes.

Pfizer have an approved weekly 20mg/m² dosage ("although, objective responses have been seen at 16mg/m2")

https://www.ctc.ucl.ac.uk/TrialDocuments/Uploaded/Doxorubicin%20Solution%20for%20Injection%20-%20%20Pfizer%20SPC%20-%2018.03.2010_15072020_0.pdf

so my logic was that two-thirds of the highest non-MTD might be an acceptable starting dose, so 256mg/m2 if C7's 385mg/m2 has been trialled long enough for the FDA to assess the data.

All speculation of course, but I see this fortnightly dosing trial as a way to quickly escalate up the dosing. The clinicians and Avacta must have been getting really frustrated (as well as elated) to see another and then yet another dose escalation and no MTD in sight.

Yes, cummulative effects will be more prominent in a fortnightly dosing regimen, and consequently crucial. Something like alopecia may be more pronounced (but as not life threatening I discount that when the alternative is death), near continual nausea or vomitting would be very unpleasant and one might wish for death. A cummulative effect on blood cell efficiency is clearly life threatening and to be avoided. Easy to monitor though so if fortnightly dosing were to be approved, patients could be switched to 3-weekly if their blood cell count went down. It wouldn't be possible to switch the other way for a 3-weekly approved product, so it's all good. Massive confidence in the Avacta team and their trial clinicians.

An assumption, but I was assuming that, as this was being regulated by the FDA, they would continue with their specification of a maximum 25% increase each time.

Bella, hopefully they will put us out of our misery before too long.

Meant the interims Q&A, not the Vox Markets interview.🙄

...when you're finally back in profit!

🔔

I've just been listening to Alan's recent talks about AVA6000, specifically about the fortnightly dosing trial. In the Vox Markets interview he says "We'll be starting in the middle of the dose range and we would expect 2, 3 dose escalations, maybe 4 at most."

https://youtu.be/LKoI83jSpDM?si=mlgqEWM7K5SJbmbm&t=2920 (48:40)

Now, does he mean dose ESCALATIONS or dose escalation COHORTS?

Four dose escalations from 256mg/m² could take us to 625mg/m² (5.6 times the 75mg/m² doxorubicin dose, 7.0 times the 60mg/m² dose)😨😱 Even four dose escation cohorts would be 500mg/m²...

So thoughts on that...

Firstly, the clinicians (and the FDA) would have to be VERY sure of safety in all individuals - beware the patient(s) with the slightly different physiology.

And secondly, either Alan wasn't thinking in detail about how high that 3rd and 4th dose could get (unlikely) or he's thinking of starting at a lower intial dose, say 200mg/m². Whilst that would rightly be cautious, there would surely be no difference between a 3-weekly and a 2-weekly dosing regimen until the third week, so I wonder what data they have on the extent of 'healthy' tissue cell damage and side-effects recovery from AVA6000 after two weeks. For instance, if nausea were to last for 2 weeks, then the relief offered by a 3-weekly dosing regimen might be welcomed! Similarly for blood cell count.

It'll be very interesting to hear the trial details when they are announced!

For as long as analysts/commentators write without reasoning such clichés as: "Results from its clinical trials may disappoint the market in the future" (Jackson Wong, https://goodmoneyguide.com/analysis/are-avacta-shares-a-buy/) then the well researched PI will have an advantage over 'The Market'.